Toripalimab
![FDA Delay Coherus' Approvals for PD-1 Inhibitor and Neulasta Biosimilar Injector](https://pharmtales.com/wp-content/uploads/2023/09/FDA-Delay-Coherus-Approvals-for-PD-1-Inhibitor-and-Neulasta-Biosimilar-Injector.jpg)
FDA Delay Coherus’ Approvals for PD-1 Inhibitor and Neulasta Biosimilar Injector
Anika Sharma
Coherus BioSciences has experienced a challenging journey in seeking FDA approval for its PD-1 inhibitor, toripalimab, developed in partnership with ...
![ASCO 2023: Unlocking the Potential of TGF-β Inhibition: GFH018 and Toripalimab Combination Therapy in Immunotherapy-Resistant Patients](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023_-Empowering-Responses-in-Follicular-Lymphoma_-Epcoritamab-Combines-with-Rituximab-and-Lenalidomide-to-Unleash-Promising-Outcomes-2.jpg)
ASCO 2023: Unlocking the Potential of TGF-β Inhibition
SG Tylor
ABSTRACT NUMBER: 6026 Recent studies have underscored the crucial role of the TGF-β signalling pathway in shaping the immune microenvironment ...